Detalhe da pesquisa
1.
Essential thrombocythemia: challenges in clinical practice and future prospects.
Blood
; 141(16): 1943-1953, 2023 04 20.
Artigo
Inglês
| MEDLINE | ID: mdl-36379024
2.
Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.
Ann Hematol
; 103(2): 443-448, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38072850
3.
Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.
Ann Hematol
; 103(3): 737-747, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38263537
4.
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Ann Hematol
; 103(1): 97-103, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37946031
5.
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Am J Hematol
; 99(4): 697-718, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38269572
6.
Successful management of VTE with essential thrombocythemia and cavernous transformation of the portal vein in early pregnancy: a case report.
BMC Womens Health
; 24(1): 211, 2024 Apr 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38566064
7.
Clinical Phenotype and Outcomes of Pulmonary Hypertension Associated with Myeloproliferative Neoplasms: A Population-based Study.
Am J Respir Crit Care Med
; 208(5): 600-612, 2023 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37311222
8.
Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression.
Int J Mol Sci
; 25(7)2024 Apr 05.
Artigo
Inglês
| MEDLINE | ID: mdl-38612873
9.
HRAS mutation positive multiple myeloma in the type 2 CALR mutation positive essential thrombocythemia: A case report.
J Cell Mol Med
; 27(2): 299-303, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36606310
10.
Clinical and molecular characteristics of forty Chinese children with essential thrombocythemia: A single-center, retrospective analysis.
Br J Haematol
; 201(3): 520-529, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36695443
11.
Characterization of myeloproliferative neoplasms in the paediatric and young adult population.
Br J Haematol
; 201(3): 449-458, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36647302
12.
Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms.
Cancer Invest
; 41(5): 423-431, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-36883674
13.
Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China.
Ann Hematol
; 102(8): 2097-2107, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37354213
14.
The Combination of JAK2V617F Allele Burden and WT1 Expression can Be Helpful in Distinguishing the Subtype of MPN Patients.
Cancer Control
; 30: 10732748231163648, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36895113
15.
Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia.
Eur J Haematol
; 110(2): 131-136, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36208190
16.
Identification of putative noncanonical driver mutations in patients with essential thrombocythemia.
Eur J Haematol
; 110(6): 639-647, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36811253
17.
Myeloid Sarcoma of the Breast as Blast Phase of JAK2-Mutated (Val617Phe Exon 14p) Essential Thrombocythemia: A Case Report and a Systematic Literature Review.
Pathobiology
; 90(2): 123-130, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-35850113
18.
A Retrospective Chart Review of 809 Patients with Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices.
Acta Haematol
; 146(1): 26-36, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36001945
19.
Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype.
Acta Haematol
; 146(1): 14-25, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36349787
20.
Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms.
Mol Biol Rep
; 50(7): 5687-5695, 2023 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-37209326